More Vertex Info

-- Additional clinical progress and telaprevir data anticipated in the
   second half of 2007
-- The Company recently submitted telaprevir data from the ongoing
       PROVE 1 and PROVE 2 clinical trials to the U.S. Food and Drug
       Administration (FDA). The Company has scheduled a meeting with
       the FDA to review these data.

    -- Vertex expects to report interim data from the PROVE 1 trial at
       the 47th Annual Interscience Conference on Antimicrobial Agents
       and Chemotherapy (ICAAC) in September and expects to report
       interim data from PROVE 1 and PROVE 2 at the 58th Annual
       Meeting of the American Association for the Study of Liver
       Diseases (AASLD) in November.

    -- Vertex expects that in the second half of 2007, additional
       trials will be initiated to evaluate telaprevir in certain
       important sub-populations of HCV patients, as well as to
       explore the potential for twice-daily dosing of telaprevir in
       combination with peg-IFN and RBV.
                                                                                                                                   Ron